Prevencio, Inc., a leader in AI-powered blood tests for cardiovascular diagnostics, announces that the United States Patent and Trademark Office has issued a patent for its highly accurate blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery disease, also referred to as obstructive heart disease. The company utilized its Artificial Intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CADhs.
“Prevencio is pleased with the advancement of our patent portfolio, which is crucial for maintaining our competitive advantage,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “This is the fourth patent issued for our novel AI-driven, multiple protein blood tests. We have several more patents pending.”
In research conducted with Massachusetts General Hospital, HART CADhs demonstrated an 86% AUC accuracy, outperforming standard-of-care tests such as exercise, echocardiography and nuclear stress tests which collectively had an accuracy of 52% AUC.
Also Read: MasterControl Makes GxPAssist AI Generally Available to Streamline Life Science Processes
Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association (AHA), the U.S. spends approximately $318 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, AHA projects that 45% of the U.S. adult population will have cardiovascular disease, with healthcare-related expenditures exceeding $1 trillion.
Rhyne added, “Given the cost, complexity, and pervasiveness of cardiovascular disease, our highly accurate and accessible HART blood tests are well-positioned to improve patient outcomes while reducing costs.”
In addition to the HART CADhs test for diagnosing heart artery obstruction, Prevencio offers a second multi-protein blood test, HART CVE, which assesses one-year risk of a heart attack, stroke or cardiovascular death. HART CADhs and HART CVE tests are currently available to medical professionals for patient use.
Source: Businesswire